Want to see SE:SCIB full AI Analyst Report?
Top Page
SciBase Holding AB
(SCIB)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr18.00
▲(5354.55% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily held down by weak financial fundamentals—very large losses and substantial ongoing cash burn—despite improving revenue growth and a healthy gross margin. Technicals also remain bearish with the price below major moving averages, while valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Improving Revenue Growth
The acceleration in revenue growth indicates improving commercial traction after a weak prior year. A steadily expanding revenue base can increase operating leverage over time, broaden clinical adoption, and provide a stronger foundation for scaling the Nevisense business.
Negative Factors
Severe Persistent Losses
The scale of current losses shows that the cost base remains far ahead of revenue, despite improving sales and gross profitability. Persistent operating losses can delay self-funded growth, require difficult cost actions, and prevent the company from converting commercial progress into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue Growth
The acceleration in revenue growth indicates improving commercial traction after a weak prior year. A steadily expanding revenue base can increase operating leverage over time, broaden clinical adoption, and provide a stronger foundation for scaling the Nevisense business.
Read all positive factors
SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr189.17M
Dividend YieldN/A
Average Volume (3M)4.35K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue Growth51.21%
EPS Growth42.24%
CountrySE
Employees50
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-15.91
Shares Outstanding10,225,300
10 Day Avg. Volume3,072
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.33
Revenue Forecast (FY)kr65.90M
SciBase Holding AB Business Overview & Revenue Model
Company Description
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their k...
How the Company Makes Money
SciBase makes money primarily by selling and supporting its skin cancer detection solution (Nevisense) to healthcare providers and clinical customers. Revenue typically comes from (1) sales of capital equipment (the Nevisense device/system) placed...
SciBase Holding AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.40M | 40.46M | 29.70M | 23.25M | 17.89M | 11.73M |
| Gross Profit | 29.14M | 27.10M | 21.08M | 16.04M | 11.23M | 6.58M |
| EBITDA | -80.74M | -81.49M | -57.59M | -51.83M | -39.33M | -38.58M |
| Net Income | -97.52M | -87.06M | -61.13M | -55.59M | -39.90M | -41.69M |
Balance Sheet | ||||||
| Total Assets | 72.98M | 52.17M | 61.73M | 64.33M | 49.85M | 85.46M |
| Cash, Cash Equivalents and Short-Term Investments | 37.15M | 22.60M | 11.24M | 34.12M | 18.83M | 65.61M |
| Total Debt | 23.21M | 23.03M | 4.18M | 6.80M | 8.12M | 2.86M |
| Total Liabilities | 42.76M | 45.51M | 25.08M | 21.28M | 24.62M | 14.66M |
| Stockholders Equity | 30.22M | 6.66M | 36.65M | 43.06M | 25.24M | 70.80M |
Cash Flow | ||||||
| Free Cash Flow | -98.42M | -84.81M | -57.81M | -52.37M | -44.85M | -40.12M |
| Operating Cash Flow | -97.78M | -84.58M | -57.38M | -51.98M | -44.47M | -39.50M |
| Investing Cash Flow | -733.00K | -228.00K | -428.00K | -383.00K | -381.00K | -526.00K |
| Financing Cash Flow | 111.83M | 96.29M | 34.91M | 67.68M | -2.48M | 64.22M |
SciBase Holding AB Technical Analysis
Negative
0.33
Price Trends
28.18
Negative
35.81
Negative
31.91
Negative
Market Momentum
-3.06
Negative
21.18
Positive
40.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 22.19, below the 50-day MA of 28.18, and below the 200-day MA of 31.91, indicating a bearish trend. The MACD of -3.06 indicates Negative momentum. The RSI at 21.18 is Positive, neither overbought nor oversold. The STOCH value of 40.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.
SciBase Holding AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr54.67B | 88.87 | 30.26% | 0.82% | 13.94% | 5.70% | |
60 Neutral | kr1.36B | -274.06 | -1.22% | ― | 34.05% | -144.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | kr510.16M | -4.32 | -37.43% | ― | 27.40% | 26.07% | |
43 Neutral | kr253.31M | -6.50 | -100.09% | ― | 65.82% | 41.28% | |
42 Neutral | kr189.17M | -1.15 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr39.20M | -0.19 | -57.15% | ― | ― | 16.02% |
* General Sector Average
SE:SCIB
SciBase Holding AB
18.30
-9.20
-33.45%
SE:PAX
Paxman AB
59.80
-18.60
-23.72%
SE:SEZI
Senzime AB
3.07
-3.73
-54.85%
SE:SPEC
SpectraCure AB
0.02
-0.10
-81.60%
SE:SECT.B
Sectra AB Class B
290.60
-34.30
-10.56%
SE:ACARIX
Acarix AB
0.22
-0.10
-30.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.